The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines

The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines

Author Moura, L. R. de Google Scholar
Marshall, J-C Google Scholar
Di Cesare, S. Google Scholar
Fernandes, B. F. Google Scholar
Antecka, E. Google Scholar
Burnier, M. N. Google Scholar
Institution McGill Univ
Henry C Witelson Ocular Pathol Lab
Inst Brasileiro Oftalmol
Universidade Federal de São Paulo (UNIFESP)
Abstract Purpose Our aim was to evaluate the potential effect of imatinib mesylate (IM), a small molecule that specifically inhibits the tyrosine quinase receptors, on the proliferation and invasive abilities of two human retinoblastoma (Rb) cell lines. Furthermore, the ability of IM to radiosensitize Rb cells was evaluated. the potential targets of IM (C-kit, PDGRF-alpha and -beta, and c-Abl) were also investigated in these cell lines.Methods Two human Rb cell lines (WERI-RB-1 and Y79) were cultured under normal growth conditions. An MTT-based proliferation assay and a Matrigel invasion assay were performed with and without exposure to 10 mu M of IM. the cells were also irradiated with graded dosages of 0, 2, 4, 6, 8, and 10 Gy with and without IM and their proliferations rates were analyzed. Western blot and immunocytochemical analysis of cytospins were performed to evaluate the expression of C-kit, PDGRF-alpha and -beta, and c-Abl.Results When IM was added to both cell lines a statistically significant (P<0.05) reduction in proliferation and invasive ability were observed. Exposure to IM also significantly increased the radiosensitivity of both Rb cell lines. the c-Abl expression was strongly positive, PDGRF-alpha and -beta expression were also positive but the C-kit expression was negative in both cell lines.Conclusions These results indicate that Gleevec may be useful as an adjuvant treatment in Rb patients, specially those considered for radiation therapy. Eye (2013) 27, 92-99; doi:10.1038/eye.2012.231; published online 16 November 2012
Keywords retinoblastoma
cell lines
imatinib mesylate
tyrosine kinase
Language English
Sponsor PAAO
McGill University
Date 2013-01-01
Published in Eye. London: Nature Publishing Group, v. 27, n. 1, p. 92-99, 2013.
ISSN 0950-222X (Sherpa/Romeo, impact factor)
Publisher Nature Publishing Group
Extent 92-99
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000313557200013

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account